Table 2 Summary of imatinib mesylate efficacy in patients with locally advanced or recurrent diffuse-type TGCT.

From: Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor

Parameter

Patients N (%)

RECIST best response*

Complete remission

2 (4)

Partial response

15 (27)

Stable disease

36 (65)

Progressive disease

2 (4)

Overall response rate

17 (31)

Rate of disease control

53 (96)

Symptomatic response

40 (78)**

Median IM treatment duration (IQR), mo.

9.3 (5–26)

Median PFS (IQR), mo.

18 (8–55)

  1. Abbreviations: TGCT = Tenosynovial Giant Cell tumour, IM = imatinib mesylate, N = Number of patients, mo = months, yrs = years, IQR = inter quartile range.
  2. Overall response rate includes complete remission and partial response; Rate of disease control includes complete remission, partial response and stable disease; Symptomatic response was indicated as present or not (40/51 = 78%). Metastatic patients (n = 4) were excluded.
  3. *N = 3 RECIST best response not available; **N = 9 symptomatic response not available.
Back to article page